Tiziana Life Sciences (TLSA) Non-Current Assets (2017 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Non-Current Assets of $2.9 million for Q4 2025, up 18293.75% year-over-year from N/an in Q4 2024, and up 16250.0% quarter-over-quarter from $18000.0 in Q2 2025.
Tiziana Life Sciences (TLSA) Non-Current Assets (2017 - 2025) Analysis & Trends
Tiziana Life Sciences' Non-Current Assets history runs 9 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 18293.75% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $12.2 million (up 76287.5% YoY), while the FY2025 annual figure was $2.9 million, up 18293.75% from the prior year.
- Non-Current Assets for Q4 2025 stood at $2.9 million, up from $18000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $4.8 million in Q4 2023, with the low at $16000.0 in Q2 2024.
- The 5-year median for Non-Current Assets is $1.5 million (2022), against an average of $1.6 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets tumbled 99.67% in 2024, then soared 18293.75% in 2025.
- Tiziana Life Sciences' Non-Current Assets stood at $147000.0 in 2021, then surged by 1393.2% to $2.2 million in 2022, then surged by 120.82% to $4.8 million in 2023, then sank by 99.67% to $16000.0 in 2024, then jumped by 18293.75% to $2.9 million in 2025.
- Business Quant data shows TLSA's Non-Current Assets at $2.9 million in Q4 2025, $18000.0 in Q2 2025, and $16000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Tiziana Life Sciences | 133.66 Mn | 129.65 Mn | - | 2.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.94 Mn |
| Jun 30, 2025 | 18,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Dec 31, 2023 | 4.85 Mn |
| Jun 30, 2023 | 2.24 Mn |
| Dec 31, 2022 | 2.20 Mn |
| Jun 30, 2022 | 2.81 Mn |
| Dec 31, 2021 | 147,000.00 |
| Jun 30, 2021 | 724,023.24 |
| Dec 31, 2020 | 475,362.36 |
| Jun 30, 2020 | 658,098.67 |
| Dec 31, 2019 | 853,721.34 |
| Jun 30, 2019 | 746,061.32 |
| Dec 31, 2018 | 286,949.09 |
| Jun 30, 2018 | 311,979.26 |
| Dec 31, 2017 | 23,897.97 |